Stockreport

ARMO BioSciences Announces Positive Outcome of First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study

ARMO BIOSCIENCES  (ARMO) 
US:NASDAQ Investor Relations: armobio.com
PDF Data Monitoring Committee Recommends Study Proceed Without Modification REDWOOD CITY, Calif., March 26, 2018 (GLOBE NEWSWIRE) -- ARMO BioSciences, Inc. (Nasdaq:ARMO), [Read more]